Kenneth Lippel
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kenneth Lippel.
Clinica Chimica Acta | 1979
Paul S. Bachorik; Peter D. Wood; Jackie Williams; Myron Kuchmak; Susan W. Ahmed; Kenneth Lippel; John J. Albers
The automated (AutoAnalyzer II) determination of cholesterol in nine serum pools in the concentration range 3.465-8.871 mmol/l, gave results that were approximately 10% higher than reference values when the analyses were based on unesterified cholesterol standards containing the same amount of water as the sample extracts (1963 analyses in 12 laboratories during a 12 month period; automated value = 0.032 + 1.10 X (Reference value)). A serum calibration procedure was successful ilues, and was equally effective in correcting the values observed for aliquots of 368 fresh-frozen plasma samples analyzed in each of the 12 laboratories during a 38 month period.
Controlled Clinical Trials | 1983
Robert L. Habig; Paul Thomas; Kenneth Lippel; Deborah Anderson; John M. Lachin
This article presents the rationale, selection, operation, and quality control of the Central Serum and Central Bile Laboratories utilized by the National Cooperative Gallstone Study. The external quality control protocols were designed to monitor long-term stability of the analytical procedures and to measure the precision of the measurements as affected by the collection, labelling, storage, shipping, and laboratory methods. For both laboratories, the assessment of long-term stability by pool standards failed to produce the data necessary to come to relevant conclusions. Several of the problems involved, however, did lead to protocol changes that increased the reliability of the laboratory data. The use of duplicate measurements to monitor precision was more successful and demonstrated acceptable performance of these systems. This article describes the external quality control surveillance procedures employed in the NCGS, their strengths and weaknesses, statistical methods for the analysis of such quality control programs, and the implications for the final statistical analyses of the clinical trial patient data.
JAMA | 1994
Ernst J. Schaefer; Stefania Lamon-Fava; Jennifer L. Jenner; Judith R. McNamara; Jose M. Ordovas; C. Edward Davis; Jeffrey M. Abolafia; Kenneth Lippel; Robert I. Levy
JAMA | 1993
Clifford L. Johnson; Basil M. Rifkind; Christopher T. Sempos; Margaret D. Carroll; Paul S. Bachorik; Ronette Briefel; David J. Gordon; Vicki L. Burt; Clarice Brown; Kenneth Lippel; James I. Cleeman
JAMA | 1993
Christopher T. Sempos; James I. Cleeman; Margaret D. Carroll; Clifford L. Johnson; Paul S. Bachorik; David J. Gordon; Vicki L. Burt; Ronette Briefel; Clarice Brown; Kenneth Lippel; Basil M. Rifkind
JAMA | 1986
David M. DeLong; Elizabeth R. DeLong; Peter D. Wood; Kenneth Lippel; Basil M. Rifkind
Clinical Chemistry | 1977
Kenneth Lippel; S Ahmed; J J Albers; Paul S. Bachorik; G Cooper; R Helms; J Williams
Clinical Chemistry | 1978
Kenneth Lippel; S Ahmed; J J Albers; Paul S. Bachorik; R Muesing; C Winn
Controlled Clinical Trials | 1995
Peter D. Wood; Gerald Kessler; Kenneth Lippel; Marcia L. Stefanick; Carol Wasilauskas; H.Bradley Wells
Clinical Chemistry | 1980
P D Wood; Paul S. Bachorik; John J. Albers; C C Stewart; C Winn; Kenneth Lippel